STOCK TITAN

MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth

(Neutral)
(Positive)
Tags

eXeX, a Surgery Intelligence company, appointed Max Reinhardt as President, Healthcare, to lead commercial execution of its Canopus platform across hospital systems in the United States, the United Kingdom and other markets. Reinhardt brings more than three decades of MedTech and pharmaceutical leadership, including 17 years at Johnson & Johnson and President-level roles at Orthofix Medical (NASDAQ: OFIX), Pacira BioSciences and DePuy Synthes.

Canopus by eXeX is described as the first Surgery Intelligence platform, delivering OR-, surgeon- and procedure-specific setup and step-by-step execution plans in real time using touch-free technology, without EHR integration or patient data. According to eXeX, the system aims to reduce surgeon cognitive load, support OR teamwork and improve OR productivity, and is already deployed across multiple hospital groups in the US and UK, having supported several thousand live surgeries, initially in complex spine and orthopedics.

eXeX also introduced Canopus Command, an intelligent portal giving hospital staff and leadership a live operational view into every surgical case, exposing real-time metrics such as setup accuracy, workflow timing, supply utilization and onboarding velocity. A key metric in Canopus Command is the “Surgical Inquiry” – the moment a team member pulls the exact information needed for the case – which can be tracked across facilities to show where information demand is concentrating by procedure, team and workflow stage, enabling leadership to allocate resources ahead of need. Reinhardt joins recently appointed COO John Spranger and Chairman/CEO Dr. Robert Masson to drive the company’s stated goal of bringing Canopus to every OR, for every surgeon and every surgery.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – OFIX

+0.61%
6 alerts
+0.61% Session close to close
$467.27M Market Cap
0.3x Rel. Volume

In the Jul 21 session, OFIX gained 0.61%, reflecting a mild positive market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Insider data recorded Net Buying, with 428985 shares bought and 3670 shares sold during the 90-day w...
Analysis

Insider data recorded Net Buying, with 428985 shares bought and 3670 shares sold during the 90-day window. Against that backdrop, the eXeX appointment is a leadership and commercialization update; execution evidence remains the key watchpoint, with low short positioning.

Key Figures

Supported surgeries: several thousand live surgeries Executive experience: more than three decades Johnson & Johnson tenure: seventeen years +5 more
8 metrics
Supported surgeries several thousand live surgeries Canopus deployment
Executive experience more than three decades MedTech and pharmaceutical leadership
Johnson & Johnson tenure seventeen years Career history
Orthopedics revenue responsibility $5.5 billion DePuy Synthes accountability
Orthofix role year 2024 President, Global Spine
Pacira role year 2019 President, Pacira BioSciences
DePuy Synthes Spine role year 2013 Worldwide President
Global spine market position number-two market-share position Worldwide DePuy Synthes Spine leadership

Historical Context

5 past events · Latest: Jul 15 (Neutral)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Jul 15 Earnings date notice Neutral +3.1% Scheduled second-quarter results release and conference call for August 5
May 18 Investor conferences Neutral +1.1% Participation announced for two June healthcare investor conferences
May 06 Product portfolio update Positive -2.0% FITBONE system launch and OrthoNext software enhancements were announced
May 05 First-quarter earnings Positive +3.6% Quarterly results reported and full-year financial guidance reaffirmed
Apr 21 Earnings date notice Neutral -4.3% First-quarter results release and conference call were scheduled for May 5

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive earnings updates were followed by gains, while the product-update announcement was followed by a decline.

Key Terms

cognitive load, ehr integration, craniomaxillofacial, biologics
4 terms
cognitive load medical
"The solution reduces surgeon cognitive load, facilitates effective OR teamwork"
The amount of mental effort required to understand, remember, and work with information at any moment. It describes how much of a person’s limited short-term memory is being used—like how heavy a backpack feels when you add more items or how many balls you can keep in the air while juggling. For investors, cognitive load matters because it affects how clearly financial reports, disclosures, or presentations are understood, how quickly people spot errors or key points, and how likely misunderstandings are when information is complex or dense.
ehr integration technical
"requiring no EHR integration and excluding any patient data"
EHR integration is the process of connecting electronic health record systems with other software or devices so patient data can flow smoothly between them. For investors, it matters because well-integrated EHRs reduce administrative costs, speed care delivery, enable new services or products, and lower regulatory or operational risk—similar to how connecting apps on your phone makes them more useful and increases the value of the whole system.
craniomaxillofacial medical
"joint reconstruction, trauma, craniomaxillofacial, spine, and sports medicine"
Relating to the bones and soft tissues of the skull, face, jaw and associated structures, often used to describe surgeries, implants, plates, screws, and medical devices used to repair or reconstruct those areas after injury, disease, or congenital conditions. Investors follow craniomaxillofacial markets because they involve specialized surgical products, implants, and procedures whose demand, regulatory approvals, and reimbursement policies can affect company revenues much like the orthopedic or dental device markets.
biologics medical
"leading the company's global spine and biologics business"
Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

The Johnson & Johnson, Pacira BioSciences and Orthofix executive takes charge of commercial execution as adoption of Canopus by eXeX accelerates across hospital systems in the United States and United Kingdom, and as eXeX launches Canopus Command, the first portal to give hospital leadership a live operational view into step-by-step execution of every surgical case.

ORLANDO, Fla. and LONDON, July 21, 2026 /PRNewswire/ -- eXeX, the global Surgery Intelligence company, today announced the appointment of Max Reinhardt as President, Healthcare. Reinhardt, who has held senior leadership roles in MedTech and pharmaceuticals, will drive the company's commercial execution, bringing Surgery Intelligence into hospital systems across the United States, the United Kingdom, and beyond.

Canopus™ by eXeX is the world's first Surgery Intelligence platform, designed to transform the experience in the Operating Room (OR) by presenting surgeon, surgery, and OR-specific setup and step-by-step procedure execution plans in real time. Canopus utilizes touch-free technology, digitizing the experience and knowledge of the most capable teams for every OR, every surgeon, and every surgery. The solution reduces surgeon cognitive load, facilitates effective OR teamwork, enables improved OR productivity, and is non-clinical by design, requiring no EHR integration and excluding any patient data for ease of adoption. Canopus optimizes preparation, orchestrates the OR in real time, and turns every case into a planned, structured, informed operation, with the ability for the team to continually optimize the plan as required at any time.

The appointment caps a period of accelerated quarter-over-quarter growth. Canopus is deployed across multiple hospital groups in the United States and United Kingdom and has supported several thousand live surgeries, proven first where surgery is most complex (spine and orthopedics) and built for all of surgery.

"The operating room is the most complex workspace on Earth. It deserves intelligent infrastructure, and it deserves leaders who have lived inside it," said Robert Masson, MD, Chairman and CEO of eXeX and a practicing neurological spine surgeon. "Max has spent three decades putting the world's most advanced surgical technology into the hands of teams on every continent. There is no better person to lead our commercial efforts at this exciting time."

A Career Built in the Operating Room

Reinhardt brings more than three decades of global MedTech and pharmaceutical executive leadership experience, including seventeen years with Johnson & Johnson. He started with J&J at DePuy Spine in the United Kingdom in 2002 and rose to Vice President of Worldwide Marketing for DePuy Synthes, accountable for $5.5 billion in orthopedics revenue with responsibility for joint reconstruction, trauma, craniomaxillofacial, spine, and sports medicine. His President-level roles span the industry's most competitive categories:

  • President, Global Spine, Orthofix Medical (NASDAQ: OFIX), 2024: leading the company's global spine and biologics business
  • President, Pacira BioSciences 2019: overseeing all commercial and medical affairs
  • Worldwide President, DePuy Synthes Spine (the spine division of Johnson & Johnson) 2013: driving the business to the number-two market-share position in the global spine market
  • Worldwide President, Joint Reconstruction, Sports Medicine & Power Tools, DePuy Synthes, a Johnson & Johnson company

Earlier in his career, Reinhardt held senior leadership positions with Steris and Olympus in Europe.

"I have spent thirty years bringing innovation to surgeons and operating rooms globally. eXeX is transforming one of the most complex and demanding work environments - the OR, where planning, communication, teamwork and execution are vital to a great outcome," said Reinhardt. "The best surgical teams in the world run on memory and tribal knowledge. For the first time, that experience and know-how can be captured and delivered, making every case the team's best case. This is a once-in-a-generation shift that is long overdue, and eXeX is leading it."

Reinhardt joins recently appointed Chief Operating Officer John Spranger to form the leadership team driving Surgery Intelligence. Alongside Dr. Masson, their mandate is to bring Canopus by eXeX to every OR, for every surgeon and every surgery.

eXeX Launches Canopus Command

eXeX also announced Canopus Command, an intelligent portal that gives hospital staff and leadership a live operational view inside every case. Every procedure generates operational data (setup accuracy, workflow timing, supply utilization, onboarding velocity) that until now disappeared the moment the case ended. With Canopus Command, hospitals see it in real time.

At its heart is a breakthrough measurement: the Surgical Inquiry, the discrete moment a team member pulls the exact information they need for the case in front of them. Tracked across a facility, Surgical Inquiries reveal where demand is concentrating (by procedure, by team, and by moment in the workflow) so leadership can move resources and personnel ahead of the need, not after it.

About eXeX

eXeX (Expanded Existence, Inc.) is building the operating system for surgery. Founded in 2022 and headquartered in Orlando, Florida, the company has built a patented platform, Canopus by eXeX, that is live across hospital systems in the United States and United Kingdom and expanding worldwide, providing surgical teams with workflow guidance and giving hospital leadership real-time operational visibility into every case. Learn more at exex.ai.

Media Contact
Douglas Sonders
douglas@exex.ai • 703-618-4110

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/medtech-pioneer-max-reinhardt-joins-exex-to-drive-canopus-platform-growth-302830852.html

SOURCE eXeX

FAQ

Who is Max Reinhardt and what role did he hold at Orthofix (NASDAQ: OFIX)?

Max Reinhardt is a veteran MedTech executive appointed President, Healthcare at eXeX. According to eXeX, he previously served as President, Global Spine at Orthofix Medical in 2024, leading the company’s global spine and biologics business as part of a multi-decade career in operating-room focused leadership.

What position will Max Reinhardt hold at eXeX and what is his mandate?

Max Reinhardt will serve as President, Healthcare at eXeX. According to eXeX, he will drive commercial execution of the Canopus Surgery Intelligence platform, expanding its adoption across hospital systems in the United States, the United Kingdom and other regions alongside the firm’s existing leadership team.

What is Canopus by eXeX and how does it support surgical teams?

Canopus by eXeX is described as a Surgery Intelligence platform for operating rooms. According to eXeX, it delivers surgeon-, surgery- and OR-specific setup and step-by-step execution plans in real time, using touch-free technology to digitize expert team knowledge, reduce cognitive load and support structured, optimized surgical workflows.

What is Canopus Command and what operational data does it provide to hospitals?

Canopus Command is an intelligent portal that offers a live operational view into every surgical case. According to eXeX, it surfaces metrics such as setup accuracy, workflow timing, supply utilization and onboarding velocity, and tracks “Surgical Inquiries” to show where information demand peaks across procedures and teams.

How widely is eXeX’s Canopus platform deployed across hospitals as of July 2026?

As of July 2026, Canopus is deployed across multiple hospital groups in the United States and United Kingdom. According to eXeX, the platform has supported several thousand live surgeries, demonstrating performance first in complex spine and orthopedic procedures while being designed for all surgical specialties.

Who are the key leaders driving Surgery Intelligence at eXeX alongside Max Reinhardt?

The Surgery Intelligence strategy at eXeX is led by Chairman and CEO Dr. Robert Masson, COO John Spranger and President, Healthcare Max Reinhardt. According to eXeX, this leadership team is mandated to bring the Canopus platform to every operating room, for every surgeon and surgery.